Who is sponsoring NCT02435680?

NCT02435680 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02435680?

Interventions in NCT02435680: MCS110, carboplatin, gemcitabine.

What condition does NCT02435680 study?

NCT02435680 studies Advanced Triple Negative Breast Cancer (TNBC) With High TAMs.

Is NCT02435680 still recruiting?

NCT02435680 is currently completed. Last updated 21 June 2021.

Are results published for NCT02435680?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-06-21 · How we verify

NCT02435680: TNBC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Completed Phase 2 Results posted Last updated 21 June 2021

What this trial tests

Phase 2 trial testing MCS110 in Advanced Triple Negative Breast Cancer (TNBC) With High TAMs in 50 participants. Completed in 23 March 2020.

Timeline

10 August 2015

Primary endpoint
4 January 2020

23 March 2020

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	10 August 2015
Primary completion	4 January 2020
Estimated completion	23 March 2020
Sites	23 locations across France, Hong Kong, Italy, Belgium, Austria, Taiwan, Germany, South Korea

Drugs / interventions tested

MCS110 — full drug profile →
carboplatin (Carboplatin) — full drug profile →
gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs — all drugs for Advanced Triple Negative Breast Cancer (TNBC) With High TAMs →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, female only, with Advanced Triple Negative Breast Cancer (TNBC) With High TAMs. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) Primary · 4 years

PFS Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design.

Group	Value	95% CI
All MCS110+Carboplatin+Gemcitabine	5.6	4.5 – 8.7
Carboplatin+Gemcitabine	5.5	3.5 – 7.5

Free MCS110 : Derived Pharmacokinetics (PK) Parameters: AUCtau Secondary · day 21 (end cycle 1); day 84 (end cycle 4)

AUC tau derived from day 0 to 21 (cycle 1) from day 0 to 21 (cycle 4) Cycle duration is 21 days

day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	1430	± 23.5
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	2960	± 22.7

day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	1840	± 34.9
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	3240	± 30.0

Free MCS110 : Derived Pharmacokinetics (PK) Parameters: Cmax Secondary · day 21 (end cycle 1); day 84 (end cycle 4)

day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	186	± 28.5
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	281	± 21.2

day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	240	± 14.8
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	319	± 27.8

Cmax Derived From Plasma Concentration of Carboplatin, Gemcitabine and 2',2'-Difluoro-deoxyuridine (dFdU) Secondary · day 21, day 84

day 21 (end cycle 1); day 84 (end cycle 4)

Cmax Carboplatin Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	12400	± 37.3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	12500	± 33.2
Carboplatin+Gemcitabine	11200	± 70.9

Cmax Carboplatin Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	9550	± 33.0
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	10000	± 28.9
Carboplatin+Gemcitabine	11600	± 55.0

Cmax Gemcitabine Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	2750	± 194.5
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	5480	± 95.1
Carboplatin+Gemcitabine	2370	± 484.9

Cmax Gemcitabine Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	2470	± 227.3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	3400	± 173.9
Carboplatin+Gemcitabine	8630	± 101.2

Cmax dFdU Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	39100	± 21.6
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	33900	± 19.5
Carboplatin+Gemcitabine	37700	± 28.2

Cmax dFdU Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	36600	± 88.6
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	30300	± 11.8
Carboplatin+Gemcitabine	32300	± 12.4

AUClast Derived From Plasma Concentration of Carboplatin, Gemcitabine and 2',2'-Difluoro-deoxyuridine (dFdU) Secondary · day 21, day 84

day 21 (end cycle 1); day 84 (end cycle 4)

AUC Carboplatin Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	24500	± 31.1
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	21400	± 27.3
Carboplatin+Gemcitabine	21800	± 56.0

AUC Carboplatin Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	18300	± 21.8
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	17500	± 25.0
Carboplatin+Gemcitabine	20500	± 34.6

AUC Gemcitabine Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	2390	± 157.3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	4270	± 79.3
Carboplatin+Gemcitabine	2620	± 225.5

AUC Gemcitabine Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	2410	± 115.2
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	2770	± 118.8
Carboplatin+Gemcitabine	6320	± 76.2

AUC dFdU Day 21

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	230000	± 34.7
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	181000	± 37.7
Carboplatin+Gemcitabine	231000	± 25.2

AUC dFdU Day 84

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	229000	± 31.9
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	147000	± 28.7
Carboplatin+Gemcitabine	211000	± 24.7

Total Colony Stimulation Factor -1 (CSF-I) Circulating Levels Secondary · baseline, day 1, 4, 15, 22, 43, 64, 85, 106, 127, 148

results expressed as a the ratio change from baseline expressed in percentage. Cycle duration is 21 days. These Biomarker Analyses were performed for MCS110 treated patients only.

Day 1

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	110	± 19.8
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	115	± 34.8

Day 4

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	4930	± 2280
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	4350	± 1620

Day 15

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	21600	± 8290
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	19500	± 6130

Day 22 (cycle 2 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	32000	± 9190
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	34400	± 14900

Day 43 (cycle 3 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	57900	± 14100
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	70000	± 27400

Day 64 (cycle 4 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	73600	± 16200
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	78000	± 41200

Day 85 (cycle 5 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	79300	± 27000
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	107000	± 51400

Day 106 (cycle 6 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	97500	± 15600
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	103000	± 50700

Serum C-terminal Telopeptide of Type I Collagen (CTX-I) Secondary · baseline, day 2, 4, 15, 22, 43, 64, 85, 106, 127, 148

results expressed as a the ratio change from baseline expressed in percentage. Cycle duration is 21 days. Biomarker Analyses performed for MCS110 treated patients only.

Day 2

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	79.4	± 22.8
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	85.0	± 44.0

Day 4

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	72.5	± 25.4
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	80.2	± 39.6

Day 15

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	65.6	± 44.3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	69.4	± 27.4

Day 22 (cycle 2 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	67.9	± 43.6
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	52.9	± 26.5

Day 43 (cycle 3 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	64.3	± 58.7
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	39.3	± 23.8

Day 64 (cycle 4 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	69.7	± 62.2
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	29.5	± 23.7

Day 85 (cycle 5 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	102	± 124
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	40.6	± 34.8

Day 106 (cycle 6 day 1)

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	41.2	± 13.2
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	50.2	± 45.3

Tumor Response Per RECIST v1.1 (by Local Investigator Assessment) Secondary · 4 years

CR: complete response. PR: partial response. SD: stable disease: CBR: clinical benefit rate =CR + PR + SD lasting at least for 6 months. ORR = CR + PR. Efficacy Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design.

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	8
Carboplatin+Gemcitabine	6

Non-CR/ Non-progressive disease

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	1
Carboplatin+Gemcitabine	0

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	19
Carboplatin+Gemcitabine	7

progressive disease

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	4
Carboplatin+Gemcitabine	1

unknown

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	2
Carboplatin+Gemcitabine	2

clinical benefit rate

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	10
Carboplatin+Gemcitabine	7

ORR

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	8
Carboplatin+Gemcitabine	6

Tumor Response Per RECIST v1.1 (by Local Investigator Assessment) Duration of Response Secondary · 4 years

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	9.6	3.6 – 42.5
Carboplatin+Gemcitabine	5	2.7 – 13.3

Number of Patients With at Least One MCS110 Dose Reduction, and Number of Patients With at Least One MCS110 Dose Interruption Secondary · 4 years

patients treated with MCS110 only

MCS110 dose reduction

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	5

MCS110 dose interruption

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	6
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	9

MCS110 Dose Intensity Secondary · 4 years

Relative dose intensity by categories. Patients treated with MCS110 only. The dose intensity measures the dose actually taken versus the planned dose, and is expressed in percentage: \<50%: less than 50 % of the planned dose received; 50-\<75 %: dose received is 50% or more, but less than 75 %; 75-\<90 %: dose received is 75% or more, but less than 90%; 90-\<110 %: dose received is 90% or more, but less than 110%

<50%

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	1
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	4

50-<75%

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	8
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	3

75-<90%

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	7
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	5

90-<110%

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	3

Tumor Associated Macrophage (TAM) and Tumor Infiltrating Lymphocyte (TIL) Content in Pre- and Post-dose Tumor Biopsies. Secondary · Baseline, Day 29-43

results expressed as a the ratio change from baseline expressed in percentage: Biopsies were taken at baseline and between Day 29 and Day 43. Patients treated with MCS110 only

CD163

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	42.1	± 62.1
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	43.5	± 239.5

CD8

Group	Value	95% CI
MCS110+Carboplatin+Gemcitabine	102	± 747.3
MCS110 With C1D8 Dose + Carboplatin +Gemcitabine	99.0	± 92.2

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus up to 150 days post treatment, up to maximum duration of 5 years. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

MCS110 + Carbo/Gem

Serious: 10/19 (53%)

Deaths: 1/19

MCS110 With C1D8@Dose + Carbo/Gem

Serious: 7/15 (47%)

Deaths: 1/15

All MCS110 + @Carbo/Gem Patients

Serious: 17/34 (50%)

Deaths: 2/34

Carbo/Gem

Serious: 1/15 (7%)

Deaths: 1/15

All@Patients

Serious: 18/49 (37%)

Deaths: 3/49

Serious adverse events (33 terms)

Reaction	System	MCS110 + Carbo/Gem	MCS110 With C1D8@Dose + Ca…	All MCS110 + @Carbo/Gem Pa…	Carbo/Gem	All@Patients
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—
Renal failure	Renal and urinary disorders	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Atypical haemolytic uraemic syndrome	Blood and lymphatic system disorders	—	—	—	—	—
Myocardial ischaemia	Cardiac disorders	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Obstructive pancreatitis	Gastrointestinal disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Generalised oedema	General disorders	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—
Device related infection	Infections and infestations	—	—	—	—	—
Erysipelas	Infections and infestations	—	—	—	—	—
Genital infection	Infections and infestations	—	—	—	—	—
Infection	Infections and infestations	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—
Mastitis	Infections and infestations	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Ankle fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—
Tumour associated fever	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—

Other adverse events (218 terms — click to expand)

Reaction	System	MCS110 + Carbo/Gem	MCS110 With C1D8@Dose + Ca…	All MCS110 + @Carbo/Gem Pa…	Carbo/Gem	All@Patients
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—
Periorbital oedema	Eye disorders	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—	—
Face oedema	General disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—
Chills	General disorders	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—	—

Most-reported serious reactions: Thrombocytopenia, Dyspnoea, Vomiting, Renal failure, Anaemia, Atypical haemolytic uraemic syndrome, Myocardial ischaemia, Nausea.

Data from ClinicalTrials.gov NCT02435680 adverse events section.

Sponsor's own description

To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Macrophages in immunoregulation and therapeutics.
Chen S, Saeed AFUH, Liu Q, Jiang Q, et al · · 2023 · cited 1250× · PMID 37211559 · DOI 10.1038/s41392-023-01452-1
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, et al · · 2017 · cited 796× · PMID 28716061 · DOI 10.1186/s40425-017-0257-y
Tumor-associated macrophages: from basic research to clinical application.
Yang L, Zhang Y. · · 2017 · cited 654× · PMID 28241846 · DOI 10.1186/s13045-017-0430-2
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.
Wang S, Wang J, Chen Z, Luo J, et al · · 2024 · cited 406× · PMID 38341519 · DOI 10.1038/s41698-024-00522-z
Tumor-associated macrophages: an effective player of the tumor microenvironment.
Basak U, Sarkar T, Mukherjee S, Chakraborty S, et al · · 2023 · cited 212× · PMID 38035101 · DOI 10.3389/fimmu.2023.1295257
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
Marra A, Trapani D, Viale G, Criscitiello C, et al · · 2020 · cited 209× · PMID 33088912 · DOI 10.1038/s41523-020-00197-2

Verify or expand the search:

Other trials of MCS110

Trials testing the same drug.

NCT03742349 — Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). · Phase 1 · terminated
NCT03285607 — MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor · Phase 1 · withdrawn
NCT03455764 — MCS110 With BRAF/MEK Inhibition in Patients With Melanoma · Phase 1, PHASE2 · completed
NCT02807844 — Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies · Phase 1, PHASE2 · completed
NCT01643850 — MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) · Phase 2 · completed

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02435680 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 21 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02435680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing